EUVIMEDEUVIMED entdecken
Multizentrische Studie

Medical Therapy in Patients with Moderate to Severe, Steroid-Resistant, Thyroid Eye Disease

David Toro-Tobon iD, Kharisa N Rachmasari, Elizabeth A Bradley, Lilly H Wagner, Andrea A Tooley, Janalee K Stokken, Marius N Stan iD

Thyroid® · 2023

DOI: 10.1089/thy.2023.0167 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Thyroid®, 2023. Verfasst von David Toro-Tobon und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Graves Ophthalmopathy. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Corticosteroid therapy is often employed in thyroid eye disease (TED), but its efficacy is variable. Teprotumumab and tocilizumab have been considered as effective alternatives. This study aims to evaluate their clinical outcomes and safety in patients with steroid-resistant TED.

Methods

A retrospective case–control study was conducted between 2018 and 2022 within a national multicenter health system. Thirty-seven patients with moderate to severe steroid-resistant TED treated with teprotumumab or tocilizumab (cases) were compared with steroid-naïve patients treated with similar therapy (controls). Due to lack of steroid-naïve patients treated with tocilizumab, a control subgroup for tocilizumab was not included in the analysis. Demographic and clinical characteristics were described. Proptosis, diplopia, clinical activity score (CAS), and disease severity (European Group on Graves' orbitopathy classification) were evaluated at weeks 0, 12, 24, and 52 after therapy initiation.

Results

Thirty-one patients received teprotumumab (13 cases and 18 controls) and 6 received tocilizumab (cases). The mean age was 57 years (standard deviation ±14.3), median duration of TED was 11.5 months (interquartile range [IQR]: 7.2–17.7), and median excess proptosis was 4 mm (IQR: 2–8) above the upper limit of normal for sex and race. At week 24, in the teprotumumab cases, 81% had proptosis response (reduction of ≥2 mm), 45.5% resolution of diplopia, 85.7% disease inactivation (CAS

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedGraves OphthalmopathyAdultAgedFemaleHumansMaleMiddle AgedCase-Control StudiesDrug ResistanceRetrospective StudiesSeverity of Illness IndexTreatment Outcome

Stichwörter der Autor:innen

teprotumumabthyroid eye diseasetocilizumab

Substanzen

Antibodies, Monoclonal, Humanizedteprotumumabtocilizumab

Autor:innen und Institutionen

  • Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Otorhinolaryngology, Mayo Clinic, Rochester, Minnesota, USA.

ORCID-Profile: David Toro-Tobon, Marius N Stan

Zitieren

APA

Toro-Tobon, D., Rachmasari, K. N., Bradley, E. A., Wagner, L. H., Tooley, A. A., Stokken, J. K., & Stan, M. N. (2023). Medical Therapy in Patients with Moderate to Severe, Steroid-Resistant, Thyroid Eye Disease. Thyroid®. https://doi.org/10.1089/thy.2023.0167

Vancouver

Toro-Tobon D, Rachmasari KN, Bradley EA, Wagner LH, Tooley AA, Stokken JK, et al. Medical Therapy in Patients with Moderate to Severe, Steroid-Resistant, Thyroid Eye Disease. Thyroid®. 2023. doi:10.1089/thy.2023.0167

BibTeX
@article{ToroTobon2023,
  author = {Toro-Tobon, David and Rachmasari, Kharisa N and Bradley, Elizabeth A and Wagner, Lilly H and Tooley, Andrea A and Stokken, Janalee K and Stan, Marius N},
  title = {Medical Therapy in Patients with Moderate to Severe, Steroid-Resistant, Thyroid Eye Disease},
  journal = {Thyroid®},
  year = {2023},
  doi = {10.1089/thy.2023.0167}
}
Kostenlos starten →